Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

 

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is Always Relevant, Ponatinib Raises Concerns in Long-term Use, Asciminib Safe & Active in MDR AML

November 18, 2019

0 Comments
Login to view comments. Click here to Login
Leukemia